GBT · Global Blood Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | $3.32M | $1.99M | $48.0K | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $212.13M | $155.12M | $174.56M | $131.31M | $87.81M | $61.21M |
| SG&A | $266.99M | $210.85M | $31.44M | $51.44M | $31.44M | $21.91M |
| Total Operating Expenses | $482.44M | $366.98M | $119.25M | $182.74M | $119.25M | $83.13M |
| D&A | $5.91M | $8.32M | $8.61M | $4.61M | $1.66M | $1.24M |
| Operating Income | ($287.69M) | ($243.17M) | ($281.28M) | ($182.74M) | ($119.25M) | ($83.13M) |
| Interest Expense | $104.06M | $48.94M | $31.22M | - | - | - |
| Income Tax | $477.0K | $0 | $0 | - | $0 | $0 |
| Net Income | ($303.09M) | ($247.55M) | ($266.77M) | ($174.19M) | ($117.02M) | ($82.47M) |
| EPS - Basic | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $684.72M | $494.77M | $302.24M | $275.36M | $198.33M | $92.07M |
| Accounts Receivable | $28.80M | $17.50M | $2.64M | - | - | - |
| Inventory | $58.20M | $40.22M | $1.28M | - | - | - |
| Accounts Payable | $15.10M | $19.08M | $10.62M | $6.05M | $7.18M | $4.32M |
| Current Assets | $801.97M | $632.16M | $628.00M | $485.78M | $324.31M | $149.77M |
| Total Assets | $939.21M | $724.00M | $796.10M | $617.64M | $356.72M | $202.39M |
| Current Liabilities | $88.00M | $79.03M | $71.45M | $33.77M | $26.26M | $15.52M |
| Long-term Debt | $246.35M | $148.81M | $73.56M | - | - | - |
| Total Liabilities | $742.80M | $307.85M | $217.41M | $44.84M | $37.92M | $16.08M |
| Stockholders' Equity | $196.41M | $416.16M | $578.69M | $572.80M | $318.80M | $186.31M |
| Retained Earnings | ($1.29B) | ($986.47M) | ($738.92M) | ($472.15M) | ($297.96M) | ($180.93M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($256.81M) | ($211.86M) | ($194.42M) | ($67.72M) | ($93.02M) | ($67.72M) |
| Investing Cash Flow | $12.11M | $317.31M | ($76.86M) | ($106.85M) | ($35.91M) | ($106.85M) |
| Financing Cash Flow | $434.33M | $87.12M | $298.16M | $118.14M | $235.19M | $118.14M |
| CapEx | $3.23M | $8.75M | $3.46M | $4.82M | $3.10M | $1.35M |
| Free Cash Flow | ($260.05M) | ($220.62M) | ($197.88M) | ($72.55M) | ($96.12M) | ($69.08M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.86 | 0.89 | 0.74 | 0.42 | 0.82 | 0.84 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -32.3% | -34.2% | -33.5% | -28.2% | -32.8% | -40.7% |
| Return on equity | -154.3% | -59.5% | -46.1% | -30.4% | -36.7% | -44.3% |
| Return on invested capital | -51.3% | -34.0% | -34.1% | - | - | - |
| Liquidity | ||||||
| Current ratio | 9.11 | 8.00 | 8.79 | 14.38 | 12.35 | 9.65 |
| Quick ratio | 8.45 | 7.49 | 8.77 | 14.38 | 12.35 | 9.65 |
| Cash ratio | 7.78 | 6.26 | 4.23 | 8.15 | 7.55 | 5.93 |
| Leverage | ||||||
| Debt / Equity | 1.25 | 0.36 | 0.13 | - | - | - |
| Debt / Assets | 0.26 | 0.21 | 0.09 | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -2.8x | -5.0x | -9.0x | - | - | - |
| Equity multiplier | 4.78 | 1.74 | 1.38 | 1.08 | 1.12 | 1.09 |
| Liabilities / Assets | 0.79 | 0.43 | 0.27 | 0.07 | 0.11 | 0.08 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | 0.06 | 0.05 | 0.04 | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | 6406d | 7392d | 9711d | - | - | - |
| Days payable outstanding | 1662d | 3506d | 80764d | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -18.3% | 13.5% | -53.9% | -53.2% | -43.4% | -430.7% |
| Net income growth (YoY) | -22.4% | 7.2% | -53.1% | -48.9% | -41.9% | -355.2% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -17.9% | -11.5% | -172.8% | 24.5% | -39.2% | -341.7% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -52.8% | -28.1% | 1.0% | 79.7% | 71.1% | - |
Stability scores
Piotroski F-score
FY 2021 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Global Blood Therapeutics against the 5 most active filers in the same SIC group.